Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2020-01-16 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
第八届董事局第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Shenzhen Haier Bioengineering Co., Ltd. It details the meeting date, attendance, and voting results on specific proposals such as authorization for accounts receivable transfer financing and capital increase in a subsidiary. The document does not contain financial statements or detailed financial data but rather reports on board decisions and approvals. It is not an annual or interim report, earnings release, or audit report. It is not a call transcript or investor presentation. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management. The document length is short and focused on board resolutions, confirming this classification with high confidence.
2020-01-16 Chinese
关于全资子公司获批建立广东省院士专家（企业）工作站的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval for its wholly-owned subsidiary to establish a Guangdong Province Academician Expert (Enterprise) Workstation. It discusses the strategic importance and expected benefits of this approval for the company. There are no financial statements, no mention of fiscal periods, no regulatory form references, and no indication of a report being attached or published. The content is a regulatory announcement about a corporate development related to innovation and technology collaboration. It does not fit into financial reports, earnings, management changes, or voting results. It is best classified as a Regulatory Filing (RNS) because it is a general corporate announcement that does not fit other specific categories.
2019-12-19 Chinese
关于为控股子公司提供担保实施情况的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the provision of guarantees for its controlling subsidiaries. It lists numerous guarantee contracts with banks and financial institutions, specifying guarantee amounts, contract parties, guarantee scope, and guarantee periods. The content focuses on the implementation of guarantees for financing and credit facilities for subsidiaries, which is a capital/financing activity. There is no indication that this is a full financial report, audit report, or regulatory certification. The document is lengthy (15,000 characters) and contains substantive details about financing guarantees, not just an announcement of a report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2019-12-10 Chinese
关于对外担保进展暨解除对外担保的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the progress and release of external guarantees. It details the company's guarantee obligations to another company and the status of these guarantees being fully released. The document is short (839 characters) and focuses on a specific corporate event related to guarantees, not financial results, management changes, or regulatory filings. It is not a financial report, earnings release, or management report. It is an announcement about a corporate guarantee matter, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories like Capital/Financing Update or Legal Proceedings Report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2019-11-28 Chinese
关于股东部分股份解押及质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the pledge and release of shares by the controlling shareholder of the company. It includes specific data on share quantities pledged and released, pledge purposes, and assurances about the absence of risks related to the pledges. There is no indication of financial statements, earnings data, or management discussion of financial results. The content focuses on share pledge transactions by a major shareholder, which fits the category of share pledging or capital structure changes. This is not a full financial report, earnings release, or management report. It is not a regulatory filing or announcement of a report publication. Therefore, the document is best classified as a Share Issue/Capital Change (SHA) filing, which covers announcements regarding share pledges and capital changes.
2019-11-26 Chinese
关于获得广东省科技创新战略专项资金补助的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Haiwang Bioengineering Co., Ltd. regarding the receipt of a government subsidy related to a provincial science and technology innovation fund. It details the nature of the subsidy, accounting treatment, and expected impact on the company's financials. The document is short (1014 characters) and serves as an announcement of a specific financial event (government grant) rather than a full financial report or detailed financial data. It does not contain comprehensive financial statements or detailed analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2019-11-20 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.